Natera, Inc. (NASDAQ:NTRA) Shares Bought by Rhumbline Advisers

Rhumbline Advisers lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 10.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 153,402 shares of the medical research company's stock after acquiring an additional 15,121 shares during the quarter. Rhumbline Advisers owned approximately 0.11% of Natera worth $21,693,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of NTRA. Principal Securities Inc. raised its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC increased its stake in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after buying an additional 61 shares during the period. Silver Oak Securities Incorporated increased its stake in shares of Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock valued at $470,000 after buying an additional 89 shares during the period. Colonial Trust Co SC raised its holdings in shares of Natera by 7.8% in the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock valued at $210,000 after acquiring an additional 96 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Institutional investors own 99.90% of the company's stock.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 6,111 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the completion of the transaction, the chief executive officer now directly owns 179,071 shares of the company's stock, valued at approximately $28,132,054.10. The trade was a 3.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total transaction of $471,210.00. Following the sale, the insider now directly owns 133,205 shares in the company, valued at $20,922,509.35. The trade was a 2.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,275 shares of company stock worth $10,075,783 over the last three months. Company insiders own 7.60% of the company's stock.

Natera Stock Performance

Shares of Natera stock traded up $1.03 on Tuesday, reaching $165.22. 1,188,866 shares of the stock were exchanged, compared to its average volume of 1,406,388. The business has a 50 day moving average price of $152.72 and a two-hundred day moving average price of $158.56. The firm has a market capitalization of $22.56 billion, a price-to-earnings ratio of -93.88 and a beta of 1.74. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.56) EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research reports. Morgan Stanley raised their target price on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Royal Bank of Canada assumed coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. UBS Group upped their target price on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. BTIG Research reiterated a "buy" rating on shares of Natera in a report on Friday, February 28th. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Natera has an average rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.